13F-HR filed by Foresite Capital Management IV, LLC
Foresite Capital Management IV, LLC filed this 13F-HR for the quarter ended 2022-06-30, filed 2022-08-12, with 8 holding rows worth $371,386,000.
- Accession
- 0001104659-22-089764
- Filer
- CIK 1704132
- Filed
- 2022-08-12
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2022
A holdings report, 8 entries on the cover page, a total value of $371,386,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $371,386,000 with VALUE read as thousands by filing date, 13F file number 028-18415. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| KINNATE BIOPHARMA INC | 49705R105 | COM | 9,671,643 | $121,959,000 | thousands by filing date | |
| LYELL IMMUNOPHARMA INC | 55083R104 | COM | 13,282,181 | $86,600,000 | thousands by filing date | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 3,246,926 | $71,757,000 | thousands by filing date | |
| ACLARIS THERAPEUTICS INC COM | 00461U105 | Stock | 2,808,034 | $39,200,000 | thousands by filing date | |
| KURA ONCOLOGY INC COM | 50127T109 | Stock | 1,849,947 | $33,910,000 | thousands by filing date | |
| NURIX THERAPEUTICS INC | 67080M103 | COMMON STOCK | 677,143 | $8,579,000 | thousands by filing date | |
| CYMABAY THERAPEUTICS INC | 23257D103 | COM | 1,787,094 | $5,272,000 | thousands by filing date | |
| QUANTUM SI INC | 74765K105 | COM CL A | 1,771,249 | $4,109,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-22-089764 | this filing | 2022-08-12 | acceptance time not in the bulk data set |